Genome Editing From Modeling Disease to Novel Therapeutics

The use of genome editing tools to generate specific DNA variants in hPSCs provide more accurate modeling of human disease when differentiated into human-derived tissues. View this webinar presented by Dr. Chad Cowan at Harvard University, who discussed the design and use of TALENs or CRISPR/Cas9 systems with hPSCs and the applications of modified hPSCs, including disease modeling and gene therapy.

The ability of human pluripotent stem cells (hPSCs) to differentiate into the many specialized cell types of the human body holds great promise for the study and treatment of human disease. Genome editing of hPSCs can allow for more accurate modeling of human diseases by introducing disease-specific mutations, or correct genetic aberrations in patient-derived induced pluripotent stem cell lines. Advances in tools such as transcription activator-like effector nucleases (TALENs) or clustered regularly interspaced short palindromic repeat (CRISPR) technologies have improved the ease and efficiency of genome editing in hPSCs.
Watch this free webinar featuring Dr. Chad Cowan (Harvard University) to learn how you can modify hPSC genomes and enhance the physiological relevance of your research.
  • Culture conditions for expansion and cloning of hPSCs
  • Design and use of TALENs or CRISPRs with hPSCs
  • Identification of clones without antibiotic selection
  • Applications of modified hPSCs including disease modeling
  • Use of the CRISPR/Cas system for gene therapy
Publish Date: June 20, 2014